The restricted drug distribution program iPLEDGE is for the medication:

Dofetilide is an antiarrhythmic medication used to treat certain types of irregular heartbeats. It is not subject to the iPLEDGE program, as it does not carry the same teratogenic risks associated with Isotretinoin. Instead, its usage is monitored through other regulatory frameworks related to cardiac safety.

Thalidomide is known for its severe teratogenic effects and is indeed regulated under a different risk management program called the STEPS program. While it shares some similarities with Isotretinoin in terms of safety concerns, it does not fall under the iPLEDGE program specifically, which is exclusively for Isotretinoin.

Clozapine is an antipsychotic used for treatment-resistant schizophrenia and carries risks related to agranulocytosis, which necessitates monitoring, but it is not associated with the iPLEDGE program. Its regulation is focused on blood cell counts rather than pregnancy prevention, thus making it unrelated to the iPLEDGE requirements.